Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia
Vigil Neuroscience to Present at 2022 Jefferies Global Healthcare Conference
Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights
Vigil Neuroscience Expands Leadership Team and Board of Directors
Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
Vigil Neuroscience to Present at Stifel 2022 CNS Days
Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology Annual Meeting
Vigil Neuroscience Announces Closing of Initial Public Offering
Vigil Neuroscience Announces Pricing of Initial Public Offering